Rasburicase
Detoxifying Agents For Antineoplastic Treatment
Sold as Elitek · FASTURTEC
- Drug class
- Detoxifying Agents For Antineoplastic Treatment
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 4
- FDA reports (12 mo)
- 136
Overview
Rasburicase is an active pharmaceutical ingredient in the Detoxifying Agents For Antineoplastic Treatment group (V03AF). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | May 8, 2025 |
| GB United Kingdom | MHRA | 1 | May 1, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
| EU European Union | EMA | 1 | August 12, 2024 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
Elitek is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
( 1 ) Limitations of use: Elitek is indicated only for a single course of treatment. 1) ] .
How to take
GBUnited Kingdom· MHRA
1 product
Uses
Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
How to take
CACanada· Health Canada
1 product
Uses
FASTURTEC (Rasburicase for injection) is indicated for: • the treatment and prophylaxis of hyperuricemia in pediatric and adult cancer patients. 1 Pediatrics Pediatrics (1 month – 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Fasturtec in pediatric patients have been established.
Therefore, Health Canada has authorized an indication for pediatric use.
How to take
EUEuropean Union· EMA
1 product
Uses
Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
How to take
Drug interactions
Known interactions involving Rasburicase. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0ae10bc4-6b65-40… · revised May 8, 2025 [PDF]
- [2]MHRA (UK) · PLGB044250821 · revised May 1, 2026
- [3]Health Canada (DPD) · 02248416 · revised March 22, 2025
- [4]European Medicines Agency · EMEA/H/C/000331 · revised August 12, 2024
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.